Penn Pancreatic Cancer Research Center

  • PCRC Team at PurpleStride November 4, 2017 (Kneeling in front row, PCRC Director Dr. Ben Z. Stanger and team captain Trish Gambino, RN)

  • Murine pancreatic tumor with cancer cells stained in green (YFP), nuclei in blue (DAPI) and collagen in purple - Captured by Nicole Aiello (Stanger Lab)

  • The PCRC Team at The Lustgarten Foundation walk November 6, 2016 in Pennsauken, NJ

  • Pancreatic tumor cells stained for YFP (cyan), E - Cadherin (red), Cytokeratin-19 (green), with nuclei counterstained with DAPI (blue) - Amine Sahmoud (Stanger Lab)

Welcome to the Penn Pancreatic Cancer Research Center!

The Penn Pancreatic Cancer Research Center (PCRC) is committed to delivering high-quality care for patients with pancreatic cancer. We take a multidisciplinary approach — integrating Medical Oncology, Surgery, Gastroenterology, Radiation Oncology, and Pathology — to deliver comprehensive and personalized options to our patients.

The American Cancer Society has reported that in 2018 pancreatic cancer became the third leading cause of cancer death in the U.S., surpassing breast cancer (see Cancer Statistics). One encouraging piece of this report is that the five-year relative survival rate for pancreatic cancer has moved to 10* percent (from 5 percent several years ago). At the Penn Pancreatic Cancer Research Center (PCRC), we understand the urgent need to develop better treatments and cures for patients.

Kim Vernick, pancreatic cancer survivor who received treatment at the PCRC, was featured in a Let's Win! Pancreatic Cancer video, sharing her experience beating this devastating disease. View the video here:

November Marks Pancreatic Cancer Awareness Month

As researchers and clinicians in the Penn PCRC, we honor survivors, patients, and caregivers and strive to offer Hope at All Stages.

Feature Articles

PCRC was featured in a video from Let’s Win! Pancreatic Cancer in recognition of the Hope for All Stages program at the ACC. View the video here.

Research Advances

Results from the phase 1b study of CD40 agonists with or without PD-1 inhibition for the treatment of metastatic pancreatic cancer reported in Lancet Oncology. Read more here.

For more of our published research, see the Publications page:

Information for clinical trials

We believe in the power of clinical trials in caring for patients and conquering this disease.
For more information, click here.

© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Report Accessibility Issues and Get Help | Privacy Policy | Site Design: DART Web Team.